Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, Mailankody S, Landgren O, Figg WD.

Sci Rep. 2019 Oct 16;9(1):14884. doi: 10.1038/s41598-019-51446-9.

2.

Antibody-drug conjugates for cancer.

Chau CH, Steeg PS, Figg WD.

Lancet. 2019 Aug 31;394(10200):793-804. doi: 10.1016/S0140-6736(19)31774-X. Review.

PMID:
31478503
3.

Delayed diagnosis of tuberculosis: risk factors and effect on mortality among older adults in Hong Kong.

Leung EC, Leung CC, Chang KC, Chan CK, Mok TY, Chan KS, Lau KS, Chau CH, Yee WK, Law WS, Lee SN, Au KF, Tai LB, Leung WM.

Hong Kong Med J. 2018 Aug;24(4):361-368. doi: 10.12809/hkmj177081. Epub 2018 Jul 30.

4.

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models.

Harris EM, Strope JD, Beedie SL, Huang PA, Goey AKL, Cook KM, Schofield CJ, Chau CH, Cadelis MM, Copp BR, Gustafson KR, Figg WD.

Mar Drugs. 2018 Jul 19;16(7). pii: E241. doi: 10.3390/md16070241.

5.

Revisiting 5α-reductase inhibitors and the risk of prostate cancer.

Chau CH, Figg WD.

Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9. Review. No abstract available.

6.

Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.

Chang KC, Leung EC, Law WS, Leung WM, Tai LB, Lee SN, Lam FM, Chau CH, Mok TY, Yew WW, Leung CC.

Eur Respir J. 2018 Jun 14;51(6). pii: 1800159. doi: 10.1183/13993003.00159-2018. Print 2018 Jun. No abstract available.

7.

Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China.

Cheng VCC, Sridhar S, Wong SC, Wong SCY, Chan JFW, Yip CCY, Chau CH, Au TWK, Hwang YY, Yau CSW, Lo JYC, Lee CK, Yuen KY.

Emerg Infect Dis. 2018 Jan;24(1). doi: 10.3201/eid2401.171297. Epub 2018 Jan 17.

8.

Jumping the Barrier: Modeling Drug Penetration across the Blood-Brain Barrier.

Peer CJ, Chau CH, Figg WD.

Clin Cancer Res. 2017 Dec 15;23(24):7437-7439. doi: 10.1158/1078-0432.CCR-17-2741. Epub 2017 Oct 10.

9.

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD.

Mol Cancer Res. 2017 Aug;15(8):1096-1105. doi: 10.1158/1541-7786.MCR-16-0477. Epub 2017 Apr 7.

10.

Effects of diabetes mellitus on the clinical presentation and treatment response in tuberculosis.

Leung CC, Yew WW, Mok TYW, Lau KS, Wong CF, Chau CH, Chan CK, Chang KC, Tam G, Tam CM.

Respirology. 2017 Aug;22(6):1225-1232. doi: 10.1111/resp.13017. Epub 2017 Feb 28.

PMID:
28244689
11.

The challenge of patient empowerment in hand hygiene promotion in health care facilities in Hong Kong.

Cheng VCC, Wong SC, Wong IWY, Chau PH, So SYC, Wong SCY, Chen JHK, Lee WM, Tai JWM, Chau CH, Lo WK, Yuen KY.

Am J Infect Control. 2017 May 1;45(5):562-565. doi: 10.1016/j.ajic.2016.12.007. Epub 2017 Jan 25.

PMID:
28131422
12.

Androgen receptor variation affects prostate cancer progression and drug resistance.

McCrea E, Sissung TM, Price DK, Chau CH, Figg WD.

Pharmacol Res. 2016 Dec;114:152-162. doi: 10.1016/j.phrs.2016.10.001. Epub 2016 Oct 7. Review.

13.

Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.

Beedie SL, Mahony C, Walker HM, Chau CH, Figg WD, Vargesson N.

Sci Rep. 2016 Jul 22;6:30038. doi: 10.1038/srep30038.

14.

Prevention of Contrast-Induced Renal Failure for the Interventional Cardiologist.

Chau CH, Williams DO.

Circ Cardiovasc Interv. 2016 Jun;9(6). pii: e004122. doi: 10.1161/CIRCINTERVENTIONS.116.004122. No abstract available.

PMID:
27313283
15.

Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.

Schmidt KT, Chau CH, Price DK, Figg WD.

J Clin Pharmacol. 2016 Dec;56(12):1484-1499. doi: 10.1002/jcph.765. Epub 2016 Jun 17. Review.

16.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.

17.

Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.

Goey AK, Chau CH, Sissung TM, Cook KM, Venzon DJ, Castro A, Ransom TR, Henrich CJ, McKee TC, McMahon JB, Grkovic T, Cadelis MM, Copp BR, Gustafson KR, Figg WD.

J Nat Prod. 2016 May 27;79(5):1267-75. doi: 10.1021/acs.jnatprod.5b00846. Epub 2016 May 3.

18.

In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems.

Beedie SL, Rore HM, Barnett S, Chau CH, Luo W, Greig NH, Figg WD, Vargesson N.

Oncotarget. 2016 May 31;7(22):33237-45. doi: 10.18632/oncotarget.8909.

19.

The canSAR data hub for drug discovery.

Chau CH, O'Keefe BR, Figg WD.

Lancet Oncol. 2016 Mar;17(3):286. doi: 10.1016/S1470-2045(16)00095-4. Epub 2016 Mar 2. No abstract available.

20.

Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.

Beedie SL, Peer CJ, Pisle S, Gardner ER, Mahony C, Barnett S, Ambrozak A, Gütschow M, Chau CH, Vargesson N, Figg WD.

Mol Cancer Ther. 2015 Oct;14(10):2228-37. doi: 10.1158/1535-7163.MCT-15-0320. Epub 2015 Aug 12.

21.

Melioidosis mycotic aneurysm: An uncommon complication of an uncommon disease.

Li PH, Chau CH, Wong PC.

Respir Med Case Rep. 2014 Dec 29;14:43-6. doi: 10.1016/j.rmcr.2014.12.005. eCollection 2015.

22.

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD.

PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015.

23.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

24.

Structural studies reveal thalidomide's mechanism of action and clinical effects: crystal clear or clearly complexed?

Ley AM, Chau CH, Figg WD.

Cancer Biol Ther. 2015;16(1):19-20. doi: 10.4161/15384047.2014.972828.

25.

The application of the open pharmacological concepts triple store (open PHACTS) to support drug discovery research.

Ratnam J, Zdrazil B, Digles D, Cuadrado-Rodriguez E, Neefs JM, Tipney H, Siebes R, Waagmeester A, Bradley G, Chau CH, Richter L, Brea J, Evelo CT, Jacoby E, Senger S, Loza MI, Ecker GF, Chichester C.

PLoS One. 2014 Dec 18;9(12):e115460. doi: 10.1371/journal.pone.0115460. eCollection 2014.

26.

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA.

Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.

27.

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS.

Urology. 2014 Jul;84(1):127-31. doi: 10.1016/j.urology.2014.03.015. Epub 2014 May 10.

28.

Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.

Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holly AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD.

Mol Cancer. 2014 Apr 28;13:91. doi: 10.1186/1476-4598-13-91.

29.

Angiogenesis in spontaneous tumors and implications for comparative tumor biology.

Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, de Oliveira JT, Gärtner F.

ScientificWorldJournal. 2014 Jan 19;2014:919570. doi: 10.1155/2014/919570. eCollection 2014. Review.

30.

IruO is a reductase for heme degradation by IsdI and IsdG proteins in Staphylococcus aureus.

Loutet SA, Kobylarz MJ, Chau CH, Murphy ME.

J Biol Chem. 2013 Sep 6;288(36):25749-59. doi: 10.1074/jbc.M113.470518. Epub 2013 Jul 26.

31.

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.

Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17.

32.

Aspirin desensitisation for Chinese patients with coronary artery disease.

Lee JK, Tsui KL, Cheung CY, Chau CH, Chan HL, Wu KL, Cheung GS, Choi MC, Chan KK, Li SK.

Hong Kong Med J. 2013 Jun;19(3):207-13. doi: 10.12809/hkmj133914. Epub 2013 May 6.

33.

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Chang KC, Yew WW, Cheung SW, Leung CC, Tam CM, Chau CH, Wen PK, Chan RC.

Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.

34.

Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.

Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD.

BJU Int. 2013 Jun;111(8):1269-80. doi: 10.1111/j.1464-410X.2012.11667.x. Epub 2013 Feb 18.

35.

Aflibercept in pediatric solid tumors: moving beyond the trap.

Chau CH, Figg WD.

Clin Cancer Res. 2012 Sep 15;18(18):4868-71. doi: 10.1158/1078-0432.CCR-12-2212. Epub 2012 Aug 6.

36.

Reperfusion strategy for ST-segment elevation myocardial infarction: trend over a 10-year period.

Wu KL, Tsui KL, Lee KT, Chau CH, Chan HL, Cheung SH, Cheung CY, Choi MC, Chan KK, Li SK.

Hong Kong Med J. 2012 Aug;18(4):276-83.

37.

Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.

Huang X, Chau CH, Figg WD.

J Hematol Oncol. 2012 Jul 2;5:35. doi: 10.1186/1756-8722-5-35. Review.

38.

Angiogenesis inhibitors increase tumor stem cells.

Chau CH, Figg WD.

Cancer Biol Ther. 2012 Jun;13(8):586-7. doi: 10.4161/cbt.19852. Epub 2012 Jun 1.

39.

Tolerance of moxifloxacin-containing regimens in the treatment of tuberculosis.

Fung SL, Yan SW, Chau CH, Yew WW.

Int J Tuberc Lung Dis. 2012 Feb;16(2):282-3. doi: 10.5588/ijtld.11.0600. No abstract available.

PMID:
22236937
40.

A man with a blistering eruption and tuberculosis.

Lee CH, Yuen MM, Chow WS, Tso AW, Yeung CK, Chan JC, Chau CH, Lam KS.

BMJ. 2012 Jan 6;344:d8351. doi: 10.1136/bmj.d8351. No abstract available.

PMID:
22228698
41.

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD.

J Urol. 2010 Dec;184(6):2297-302. doi: 10.1016/j.juro.2010.08.005. Epub 2010 Oct 16.

42.

Primary percutaneous coronary intervention for ST elevation myocardial infarction: performance with focus on timeliness of treatment.

Cheung GS, Tsui KL, Lau CC, Chan HL, Chau CH, Wu KL, Cheung CY, Choi MC, Tse TS, Chan KK, Li SK.

Hong Kong Med J. 2010 Oct;16(5):347-53.

43.

New tricks from an old drug: a role for quinacrine in anti-cancer therapy?

Chau CH, Figg WD.

Cell Cycle. 2009 Dec 15;8(24):4024-5. Epub 2009 Dec 15. No abstract available.

PMID:
19959937
44.

What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis?

Yew WW, Chang KC, Chau CH.

Eur Respir J. 2009 Dec;34(6):1492-4. doi: 10.1183/09031936.00111009. No abstract available.

45.

Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Yew WW, Chang KC, Chau CH.

J Antimicrob Chemother. 2009 Nov;64(5):1119; author reply 1119-20. doi: 10.1093/jac/dkp291. Epub 2009 Aug 8. No abstract available.

PMID:
19666903
46.

Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients.

Chang KC, Leung CC, Yew WW, Lam FM, Ho PL, Chau CH, Cheng VC, Yuen KY.

Int J Tuberc Lung Dis. 2009 Mar;13(3):341-6.

PMID:
19275794
47.

Elevated plasma TGF-beta1 levels in patients with chronic obstructive pulmonary disease.

Mak JC, Chan-Yeung MM, Ho SP, Chan KS, Choo K, Yee KS, Chau CH, Cheung AH, Ip MS; Members of Hong Kong Thoracic Society COPD Study Group.

Respir Med. 2009 Jul;103(7):1083-9. doi: 10.1016/j.rmed.2009.01.005. Epub 2009 Jan 31.

48.

Validation of analytic methods for biomarkers used in drug development.

Chau CH, Rixe O, McLeod H, Figg WD.

Clin Cancer Res. 2008 Oct 1;14(19):5967-76. doi: 10.1158/1078-0432.CCR-07-4535. Review.

49.

Combining mTOR inhibition with metronomic chemotherapy in targeting angiogenesis.

Chau CH, Wang W, Figg WD.

Cancer Biol Ther. 2008 Sep;7(9):1386-7. Epub 2008 Sep 6. No abstract available.

PMID:
18769127
50.

Is the whole-blood gamma interferon assay better than the tuberculin skin test in predicting active tuberculosis?

Leung CC, Chang KC, Chau CH.

Am J Respir Crit Care Med. 2008 Jul 15;178(2):210-1; author reply 211. No abstract available.

PMID:
18594123

Supplemental Content

Support Center